{"result": "(\"entity\"<|>FAUTH C<|>PERSON<|>Fauth C is an author who contributed to the research on mitochondrial DNA mutations and their clinical implications.)\n##\n(\"entity\"<|>SCHWEIGMANN U<|>PERSON<|>Schweigmann U is an author involved in the study of mitochondrial DNA mutations and their effects on health.)\n##\n(\"entity\"<|>HABERLANDT E<|>PERSON<|>Haberlandt E is an author who contributed to the literature on mitochondrial DNA mutations and their clinical manifestations.)\n##\n(\"entity\"<|>LIPOWSKI G<|>PERSON<|>Lipowski G is an author who studied the dynamics of nitric oxide in relation to mitochondrial function.)\n##\n(\"entity\"<|>LAMBRY JC<|>PERSON<|>Lambry JC is an author who researched the biochemical aspects of cytochrome c oxidase related to mitochondrial diseases.)\n##\n(\"entity\"<|>MARTIN JL<|>PERSON<|>Martin JL is an author who contributed to the understanding of nitric oxide dynamics in mitochondrial function.)\n##\n(\"entity\"<|>LIEBL U<|>PERSON<|>Liebl U is an author involved in the study of mitochondrial enzyme dynamics.)\n##\n(\"entity\"<|>TURNBULL DM<|>PERSON<|>Turnbull DM is an author who has researched mitochondrial diseases and their clinical implications.)\n##\n(\"entity\"<|>TAYLOR RW<|>PERSON<|>Taylor RW is an author who studied mitochondrial diseases and their effects on health.)\n##\n(\"entity\"<|>MCCORMACK SE<|>PERSON<|>McCormack SE is an author who contributed to the research on endocrine disorders in mitochondrial diseases.)\n##\n(\"entity\"<|>NESBITT V<|>PERSON<|>Nesbitt V is an author who participated in the UK MRC Mitochondrial Disease Patient Cohort Study.)\n##\n(\"entity\"<|>DE LAAT P<|>PERSON<|>De Laat P is an author who studied dysphagia and gastrointestinal problems in patients with mitochondrial disease.)\n##\n(\"entity\"<|>ZWEERS HEE<|>PERSON<|>Zweers HEE is an author involved in research on gastrointestinal issues in mitochondrial disease patients.)\n##\n(\"entity\"<|>KNUIJT S<|>PERSON<|>Knuijt S is an author who contributed to the study of mitochondrial disease and its complications.)\n##\n(\"entity\"<|>SMEITINK JA<|>PERSON<|>Smeitink JA is an author who researched mitochondrial diseases and their clinical implications.)\n##\n(\"entity\"<|>WANTEN GJ<|>PERSON<|>Wanten GJ is an author who studied nutritional aspects in mitochondrial disease management.)\n##\n(\"entity\"<|>JANSSEN MC<|>PERSON<|>Janssen MC is an author who contributed to the understanding of mitochondrial diseases and their treatment.)\n##\n(\"relationship\"<|>FAUTH C<|>MELAS SYNDROME<|>Fauth C's research on mitochondrial DNA mutations is relevant to the understanding of MELAS syndrome<|>5)\n##\n(\"relationship\"<|>SCHWEIGMANN U<|>MELAS SYNDROME<|>Schweigmann U's contributions to mitochondrial DNA research are significant for MELAS syndrome<|>5)\n##\n(\"relationship\"<|>HABERLANDT E<|>MELAS SYNDROME<|>Haberlandt E's work on mitochondrial DNA mutations is important for understanding MELAS syndrome<|>5)\n##\n(\"relationship\"<|>LIPOWSKI G<|>MELAS SYNDROME<|>Lipowski G's study of nitric oxide dynamics relates to mitochondrial function in MELAS syndrome<|>4)\n##\n(\"relationship\"<|>LAMBRY JC<|>MELAS SYNDROME<|>Lambry JC's research on cytochrome c oxidase is relevant to mitochondrial diseases like MELAS<|>4)\n##\n(\"relationship\"<|>MARTIN JL<|>MELAS SYNDROME<|>Martin JL's work on nitric oxide dynamics contributes to the understanding of mitochondrial function in MELAS<|>4)\n##\n(\"relationship\"<|>LIEBL U<|>MELAS SYNDROME<|>Liebl U's research on mitochondrial enzyme dynamics is relevant to MELAS syndrome<|>4)\n##\n(\"relationship\"<|>TURNBULL DM<|>MELAS SYNDROME<|>Turnbull DM's research on mitochondrial diseases is significant for understanding MELAS syndrome<|>5)\n##\n(\"relationship\"<|>TAYLOR RW<|>MELAS SYNDROME<|>Taylor RW's studies on mitochondrial diseases contribute to the understanding of MELAS syndrome<|>5)\n##\n(\"relationship\"<|>MCCORMACK SE<|>MELAS SYNDROME<|>McCormack SE's research on endocrine disorders is relevant to the complications of MELAS syndrome<|>4)\n##\n(\"relationship\"<|>NESBITT V<|>MELAS SYNDROME<|>Nesbitt V's involvement in the Mitochondrial Disease Patient Cohort Study is significant for MELAS syndrome<|>5)\n##\n(\"relationship\"<|>DE LAAT P<|>MELAS SYNDROME<|>De Laat P's research on gastrointestinal problems is relevant to the management of MELAS syndrome<|>4)\n##\n(\"relationship\"<|>ZWEERS HEE<|>MELAS SYNDROME<|>Zweers HEE's contributions to gastrointestinal issues in mitochondrial disease relate to MELAS syndrome<|>4)\n##\n(\"relationship\"<|>KNUIJT S<|>MELAS SYNDROME<|>Knuijt S's research on mitochondrial disease complications is relevant to MELAS syndrome<|>4)\n##\n(\"relationship\"<|>SMEITINK JA<|>MELAS SYNDROME<|>Smeitink JA's work on mitochondrial diseases contributes to the understanding of MELAS syndrome<|>5)\n##\n(\"relationship\"<|>WANTEN GJ<|>MELAS SYNDROME<|>Wanten GJ's research on nutritional interventions is important for managing MELAS syndrome<|>5)\n##\n(\"relationship\"<|>JANSSEN MC<|>MELAS SYNDROME<|>Janssen MC's contributions to mitochondrial disease research are significant for MELAS syndrome<|>5)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 000411.\n\n\n\n3. Pia S, Lui F. Melas Syndrome. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018\n[citado 4 de diciembre de 2018]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK532959/\n\n\n\n4. Niedermayr K, Pölzl G, Scholl-Bürgi S, Fauth C, Schweigmann U, Haberlandt E, et al. Mitochondrial\nDNA mutation “m.3243A>G”-Heterogeneous clinical picture for cardiologists (“m.3243A>G”: A pheno-\ntypic chameleon). Congenit Heart Dis. 2018; 13(5):671-677.\n\n\n\n5. Ikeda T, Osaka H, Shimbo H, Tajika M, Yamazaki M, Ueda A, et al. Mitochondrial DNA 3243A>T mu-\ntation in a patient with MELAS syndrome. Hum Genome Var. 2018;5:25.\n\n\n\n6. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary\nartery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat\nMed. 1996;2(1):41-5.\n\n\n\n7. Vos MH, Lipowski G, Lambry JC, Martin JL, Liebl U. Dynamics of nitric oxide in the active site of\nreduced cytochrome c oxidase aa3. Biochemistry.2001;40(26):7806-11.\n\n\n\n8. Koga Y, Akita Y, Junko N, Yatsuga S, Povalko N, Fukiyama R, et al. Endothelial dysfunction in MELAS\nimproved by l-arginine supplementation. Neurology. 2006;66(11):1766-9.\n\n\n\n9. Naini A, Kaufmann P, Shanske S, Engelstad K, De Vivo DC, Schon EA. Hypocitrullinemia in patients\nwith MELAS: an insight into the “MELAS paradox”. J Neurol Sci. 2005;229-230:187-93.\n\n\n\n10. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: Clinical manifestations, pathoge-\nnesis, and treatment options. Mol Genet Metab. 2015;116(1-2):4-12.\n\n\n\n11. Al-Gadi IS, Haas RH, Falk MJ, Goldstein A, McCormack SE. Endocrine Disorders in Primary Mito-\nchondrial Disease. J Endocr Soc. 2018;2(4):361-373.\n\n\n\n12. Whittaker RG, Schaefer AM, McFarland R, Taylor RW, Walker M, Turnbull DM. Prevalence and pro-\ngression of diabetes in mitochondrial disease. Diabetologia. 2007;50(10):2085-9.\n\n\n\n13. Schaefer AM, Walker M, Turnbull DM, Taylor RW. Endocrine disorders in mitochondrial disease.\nMol Cell Endocrinol. 2013;379(1-2):2-11.\n\n\n\n14. Sproule DM, Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes:\nbasic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann N Y Acad\nSci. 2008;1142:133-58.\n\n\n\n15. Nesbitt V, Pitceathly RDS, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, et al. The UK MRC\nMitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mu-\ntation--implications for diagnosis and management. J Neurol Neurosurg Psychiatry. 2013;84(8):936-8.\n\n\n\n                                                                                                           53\n---\n    16.   De Laat P, Zweers HEE, Knuijt S, Smeitink JA, Wanten GJ, Janssen MC. Dysphagia, malnutrition\n    and gastrointestinal problems in patients with mitochondrial disease caused by the m3243A&gt;G\n    mutation. Neth J Med. 2015;73(1):30-6.\n\n\n\n    17. Scaglia F, Northrop JL. The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-li-\n    ke episodes (MELAS) syndrome: a review of treatment options. CNS Drugs. 2006;20(6):443-64.\n\n\n\n    18. Camp KM, Krotoski D, Parisi MA, Gwinn KA, Cohen BH, Cox CS, et al. Nutritional interventions in\n    primary mitochondrial disorders: Developing an evidence base. Mol Genet Metab. 2016;119(3):187-206.\n\n\n\n    19. El-Hattab AW, Hsu JW, Emrick LT, Wong L-JC, Craigen WJ, Jahoor F, et al. Restoration of impaired\n    nitric oxide production in MELAS syndrome with citrulline and arginine supplementation. Mol Genet\n    Metab. 2012;105(4):607-14.\n\n\n\n    20. El-Hattab AW, Emrick LT, Hsu JW, Chanprasert S, Almannai M, Craigen WJ, et al. Impaired nitric\n    oxide production in children with MELAS syndrome and the effect of arginine\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>MELAS SYNDROME<|>EVENT<|>MELAS syndrome is a mitochondrial disorder characterized by a combination of symptoms including mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes.)\n##\n(\"entity\"<|>STATPEARLS PUBLISHING<|>ORGANIZATION<|>StatPearls Publishing is a publisher of medical literature and resources, including information on MELAS syndrome.)\n##\n(\"entity\"<|>NIEDERMAYR K<|>PERSON<|>Niedermayr K is an author who contributed to the literature on mitochondrial DNA mutations and their clinical implications.)\n##\n(\"entity\"<|>PÖLZL G<|>PERSON<|>Pölzl G is an author involved in research related to mitochondrial DNA mutations and their clinical manifestations.)\n##\n(\"entity\"<|>IKEDA T<|>PERSON<|>Ikeda T is an author who studied the mitochondrial DNA 3243A>T mutation in relation to MELAS syndrome.)\n##\n(\"entity\"<|>WANG XL<|>PERSON<|>Wang XL is an author who researched the smoking-dependent risk of coronary artery disease associated with genetic polymorphisms.)\n##\n(\"entity\"<|>KOGA Y<|>PERSON<|>Koga Y is an author who investigated endothelial dysfunction in MELAS and its improvement through l-arginine supplementation.)\n##\n(\"entity\"<|>NAINI A<|>PERSON<|>Naini A is an author who explored hypocitrullinemia in patients with MELAS syndrome.)\n##\n(\"entity\"<|>EL-HATTAB AW<|>PERSON<|>El-Hattab AW is an author who reviewed clinical manifestations, pathogenesis, and treatment options for MELAS syndrome.)\n##\n(\"entity\"<|>SCAGLIA F<|>PERSON<|>Scaglia F is an author who discussed treatment options for MELAS syndrome and its clinical implications.)\n##\n(\"entity\"<|>WHITTAKER RG<|>PERSON<|>Whittaker RG is an author who studied the prevalence and progression of diabetes in mitochondrial disease.)\n##\n(\"entity\"<|>CAMP KM<|>PERSON<|>Camp KM is an author who focused on nutritional interventions in primary mitochondrial disorders.)\n##\n(\"relationship\"<|>MELAS SYNDROME<|>STATPEARLS PUBLISHING<|>StatPearls Publishing provides literature and resources on MELAS syndrome, contributing to the understanding of the condition<|>7)\n##\n(\"relationship\"<|>NIEDERMAYR K<|>MELAS SYNDROME<|>Niedermayr K authored research related to mitochondrial DNA mutations that are significant in the context of MELAS syndrome<|>6)\n##\n(\"relationship\"<|>PÖLZL G<|>MELAS SYNDROME<|>Pölzl G contributed to the literature on mitochondrial DNA mutations relevant to MELAS syndrome<|>6)\n##\n(\"relationship\"<|>IKEDA T<|>MELAS SYNDROME<|>Ikeda T's research on mitochondrial DNA mutations is directly related to the study of MELAS syndrome<|>6)\n##\n(\"relationship\"<|>WANG XL<|>MELAS SYNDROME<|>Wang XL's research on genetic polymorphisms may provide insights into cardiovascular risks in patients with MELAS syndrome<|>4)\n##\n(\"relationship\"<|>KOGA Y<|>MELAS SYNDROME<|>Koga Y's study on endothelial dysfunction and l-arginine supplementation is relevant to the management of MELAS syndrome<|>5)\n##\n(\"relationship\"<|>NAINI A<|>MELAS SYNDROME<|>Naini A's exploration of hypocitrullinemia provides insights into metabolic aspects of MELAS syndrome<|>5)\n##\n(\"relationship\"<|>EL-HATTAB AW<|>MELAS SYNDROME<|>El-Hattab AW's review of clinical manifestations and treatment options is crucial for understanding MELAS syndrome<|>8)\n##\n(\"relationship\"<|>SCAGLIA F<|>MELAS SYNDROME<|>Scaglia F's work on treatment options for MELAS syndrome is significant for clinical practice<|>8)\n##\n(\"relationship\"<|>WHITTAKER RG<|>MELAS SYNDROME<|>Whittaker RG's research on diabetes prevalence in mitochondrial disease is relevant to the complications of MELAS syndrome<|>4)\n##\n(\"relationship\"<|>CAMP KM<|>MELAS SYNDROME<|>Camp KM's focus on nutritional interventions is important for the management of patients with MELAS syndrome<|>5)\n<|COMPLETE|>"}]}